Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation - PubMed (original) (raw)
. 2003 Nov;2(11):1093-103.
Affiliations
- PMID: 14617782
Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation
Sudhir B Kondapaka et al. Mol Cancer Ther. 2003 Nov.
Abstract
Perifosine is a novel p.o. bioavailable alkylphospholipid. Perifosine has displayed significant antiproliferative activity in vitro and in vivo in several human tumor model systems and has recently entered phase I clinical trials. Recent studies have identified that perifosine could cause cell cycle arrest with induction of p21(WAF1/CIP1) in a p53-independent fashion; however, the basis for that effect is not known. Structurally, perifosine resembles naturally occurring phospholipids. Therefore, we hypothesized that perifosine might perturb pathways related to phospholipids modulated by growth factor action. We demonstrate here that perifosine causes dose-dependent inhibition of protein kinase B/Akt phosphorylation and thus activation at concentrations causing growth inhibition of PC-3 prostate carcinoma cells. Only the myristoylated form of Akt (MYR-Akt), which bypasses the requirement for pleckstrin homology (PH) domain-mediated membrane recruitment, abrogated perifosine-mediated decrease of Akt phosphorylation and cell growth inhibition by perifosine. We demonstrate further that perifosine decreases the plasma membrane localization of Akt, and this is substantially relieved by MYR-Akt along with relief of downstream drug effect on induction of p21(WAF1/CIP1). Perifosine does not directly affect phosphoinositide 3-kinase (PI3K), phosphoinositide-dependent kinase 1, or Akt activity at concentrations inhibiting Akt phosphorylation and membrane localization. Our results demonstrate that Akt is an important cellular target of perifosine action. In addition, these studies show that the membrane translocation of certain PH domain-containing molecules can be greatly perturbed by the alkylphospholipid class of drugs and imply further that the PI3K/Akt pathway contributes to regulation of p21(WAF1/CIP1) expression.
Similar articles
- Transcriptional activation of p21(waf1/cip1) by alkylphospholipids: role of the mitogen-activated protein kinase pathway in the transactivation of the human p21(waf1/cip1) promoter by Sp1.
De Siervi A, Marinissen M, Diggs J, Wang XF, Pages G, Senderowicz A. De Siervi A, et al. Cancer Res. 2004 Jan 15;64(2):743-50. doi: 10.1158/0008-5472.can-03-2505. Cancer Res. 2004. PMID: 14744793 - Perifosine: update on a novel Akt inhibitor.
Gills JJ, Dennis PA. Gills JJ, et al. Curr Oncol Rep. 2009 Mar;11(2):102-10. doi: 10.1007/s11912-009-0016-4. Curr Oncol Rep. 2009. PMID: 19216841 Free PMC article. Review. - Novel targets of Akt, p21(Cipl/WAF1), and MDM2.
Zhou BP, Hung MC. Zhou BP, et al. Semin Oncol. 2002 Jun;29(3 Suppl 11):62-70. doi: 10.1053/sonc.2002.34057. Semin Oncol. 2002. PMID: 12138399 Review.
Cited by
- PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment.
Leiphrakpam PD, Are C. Leiphrakpam PD, et al. Int J Mol Sci. 2024 Mar 9;25(6):3178. doi: 10.3390/ijms25063178. Int J Mol Sci. 2024. PMID: 38542151 Free PMC article. Review. - Research progress on the mechanism of common inflammatory pathways in the pathogenesis and development of lymphoma.
Shi A, Yun F, Shi L, Liu X, Jia Y. Shi A, et al. Ann Med. 2024 Dec;56(1):2329130. doi: 10.1080/07853890.2024.2329130. Epub 2024 Mar 15. Ann Med. 2024. PMID: 38489405 Free PMC article. Review. - Recent advances in targeted therapy for pancreatic adenocarcinoma.
Fang YT, Yang WW, Niu YR, Sun YK. Fang YT, et al. World J Gastrointest Oncol. 2023 Apr 15;15(4):571-595. doi: 10.4251/wjgo.v15.i4.571. World J Gastrointest Oncol. 2023. PMID: 37123059 Free PMC article. Review. - Interfering with the Ubiquitin-Mediated Regulation of Akt as a Strategy for Cancer Treatment.
Paccosi E, Balzerano A, Proietti-De-Santis L. Paccosi E, et al. Int J Mol Sci. 2023 Feb 1;24(3):2809. doi: 10.3390/ijms24032809. Int J Mol Sci. 2023. PMID: 36769122 Free PMC article. Review. - Synergistic cytotoxicity of perifosine and ABT-737 to colon cancer cells.
Adamová B, Říhová K, Pokludová J, Beneš P, Šmarda J, Navrátilová J. Adamová B, et al. J Cell Mol Med. 2023 Jan;27(1):76-88. doi: 10.1111/jcmm.17636. Epub 2022 Dec 15. J Cell Mol Med. 2023. PMID: 36523175 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous